Navigation Links
Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors

sed on current expectations and involve a number of known and unknown risks and uncertainties that could cause the final results to differ significantly from the results summarized by such statements. Some of the clinical trials described in this release are being conducted by independent investigators and Pharmion does not control and cannot predict the final results of those trials. Top line or preliminary results may not be confirmed upon full analysis of the detailed results of a trial and additional information relating to the safety, efficacy or tolerability of Vidaza may be discovered upon further analysis of clinical trial data and upon review and analysis of data from other clinical trials. Additional risks and uncertainties relating to Pharmion and its business can be found in the "Risk Factors" section of Pharmion's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2007, its Annual Report on Form 10-K for the year ended December 31, 2006 and in Pharmion's other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and Pharmion undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. Pharmion also disclaims any duty to comment upon or correct information that may be contained in reports published by the investment community.

# # #

-------------------

(Back to top)

PHARMION AND METHYLGENE REPORT PRELIMINARY DATA FOR MGCD0103 AT THE 43rd AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING

HDAC INHIBITOR MGCD0103 DEMONSTRATES substantial RESPONSE RATE IN TWO CLINICAL TRIALS

40% Response Rate and 45% Disease Control Rate in Single-Agent Phase II Trial in Refractory or Relapsed Hodgkin's Lymphoma Patients

30% Response Rate (37% at Relevant Active Doses) in Phase I/II Combination Trial with Vidaza(r) in MD
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:1/23/2015)... , Jan. 23, 2015 Tianyin Pharmaceutical Inc. ... that specializes in the development and sale of patented ... and active pharmaceutical ingredients (API) today announced the business ... API operation. 1. Following the September 2014 ...
(Date:1/22/2015)... MINNEAPOLIS, Jan. 22, 2015  Uroplasty, Inc. (NASDAQ: UPI ... markets innovative proprietary products to treat voiding dysfunctions, today ... ended December 31, 2014.  Global revenue for the ... $4.4 million, a new quarterly revenue record, as compared ...
(Date:1/22/2015)... AMGN ) today announced that it will report its ... 27, 2015, after the close of the U.S. financial markets. The ... community at 2 p.m. PT. Participating in the call from Amgen ... officer, and other members of Amgen,s senior management team. ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... - First Agent Ever to Demonstrate Significant ... 04, 2007 /PRNewswire-FirstCall/ -- Bayer,HealthCare Pharmaceuticals Inc. ... (sorafenib) tablets significantly,extended overall survival in patients ... versus those taking placebo by 44%,(HR=0.69; p-value=0.0006). ...
... GAITHERSBURG, Md.--(BUSINESS WIRE)--Jun 4, 2007 - GenVec, Inc.,(Nasdaq: ... data from the clinical development program of its ... on,gastrointestinal cancers at the annual meeting of American ... Mitchell Posner, of the,University of Chicago. An oral ...
Cached Medicine Technology:Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 2Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 3Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 4Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 5Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 6Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 7GenVec Announces Update of Safety and Efficacy Data from Pivotal,Phase II/III PACT Study of TNFerade at ASCO 2GenVec Announces Update of Safety and Efficacy Data from Pivotal,Phase II/III PACT Study of TNFerade at ASCO 3GenVec Announces Update of Safety and Efficacy Data from Pivotal,Phase II/III PACT Study of TNFerade at ASCO 4
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining the main ... , Auto insurance quotes help many drivers find the ... to call an agent or visit an agency for price ... website: http://autocarinsurancebest.com/ . , Every business who relies heavily ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
(Date:1/22/2015)... Four years since the release of their debut recording Love is ... Avasa & Matthew Love – the duo are pleased to announce ... White Swan Records on February 24, 2015. , THE ROAD offers ... to all of us to walk out of the mire of ...
(Date:1/22/2015)... a famous dress online store for wedding dresses and other ... of wedding dresses , and launches a site-wide women’s dress ... on your big day; the wedding gown is the most ... find the most suitable wedding dress. Now, we are proud ...
(Date:1/22/2015)... State Forestry Institute of Mecklenburg-Vorpommern in ... support from GEOSYSTEMS, a dedicated Hexagon Geospatial and Intergraph ... Hexagon Geospatial’s ERDAS APOLLO for cataloging, managing, ... point clouds and documents. This effort will enable the ...
Breaking Medicine News(10 mins):Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... findings released today indicate that Americans awareness of nanotechnology ... the tiny nanoscale materials and nano-enabled devices and products ... technology that experts believe will usher in a new ... most Americans continue to prefer that government, not industry, ...
... Technologies Inc., a privately,held orthobiologics company, today announced that ... clearance for InQu(TM). InQu is,indicated for use as a ... bone graft,substitute in the extremities and pelvis. InQu ... optimize structural and biological properties to support bone cell,growth. ...
... as depressed, distraught were seldom questioned, study found , , ... disconnect between doctors and some of their neediest patients, ... fail to spot symptoms that raise suicide risk. ... and visit physicians while showing signs of depression or ...
... Cornell University will host more than 200 physicians ... the Northeast Wilderness Medical Conference, Sept. 26-28. Those attending ... by grappling with similar circumstances encountered in the wilderness., ... 11, 2001, disaster in New York City and the ...
... ... Disease, WHITE PLAINS, N.Y., ... with Hodgkin,lymphoma will put the blood cancer in focus. With more than ... awareness about Hodgkin lymphoma and other blood cancers. Hodgkin lymphoma begins ...
... dad in decision-making, researchers say , MONDAY, Sept. 24 (HealthDay ... participate in medical decisions made about their children while in ... parents, published in the October issue of the Journal ... confident talking with doctors, and parents whose child had been ...
Cached Medicine News:Health News:Poll reveals public awareness of nanotech stuck at low level 2Health News:Poll reveals public awareness of nanotech stuck at low level 3Health News:ISTO Technologies Receives 510(k) Clearance for a Novel Bone Graft Substitute and Bone Graft Extender 2Health News:Doctors Often Fail to Spot Suicidal Patients 2Health News:Doctors Often Fail to Spot Suicidal Patients 3Health News:In the Neighborhood: Blood Cancer Strikes Wisteria Lane 2Health News:Most Parents Have Say in Kids' Hospital Care 2
... come back with better resolution, accuracy and ... 25 or 31 rings (same as TMS-1), ... provides high accuracy & repeatability. The small ... & provides extensive corneal coverage. The low ...
... Pachycam is the first compact and ... The OCULUS Pachycam has automatic ... pressure) in accordance with Shah or ... The OCULUS Pachycam is non-contact ...
World's first commercially available vacuum assisted biopsy device for MRI....
... stereotactic, ultrasound and MRI-guided vacuum assisted breast ... Use the patented, FDA-cleared ATEC system for ... advanced method of breast biopsy. Its compassionate ... who trust YOU.,12 Gauge Handpieces: Useful for ...
Medicine Products: